Progress of biological agents on psoriatic arthritis.
Progress of biological agents on psoriatic arthritis.
复制标题
DOI：
10.2174/138920101506140910150227
复制
发表时间：
2014-05
影响因子：
2.8
通讯作者：
Yan Li;Dashan Wang;Yantang Wang;Guixiu Shi
中科院分区：
文献类型：
--
作者：
Yan Li;Dashan Wang;Yantang Wang;Guixiu Shi
银屑病性关节炎（PsA）是一种炎症性关节炎，其特征为轻度关节痛至严重关节畸形。由于缺乏疗效和潜在的器官毒性，非甾体抗炎药（NSAID）和疾病调节抗风湿药（DMARD）对这些疾病的长期管理受到限制。近年来，T细胞抑制剂和TNF-α拮抗剂等生物制剂的批准，改变了中重度银屑病和PsA的治疗方法。与NSAID和DMARD不同，TNF-α拮抗剂不仅为皮肤和关节提供明确的益处，还可预防外周关节结构损伤的进展。生物制剂在治疗PsA中具有广阔的前景。越来越多的生物制剂被开发用于治疗PsA。本文就近年来生物制剂治疗银屑病的研究进展作一综述。
Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.